... who started infliximab (IFX) treatment and their capacity to predict the response to IFX. Methods: A total of 30 active CD patients receiving an induction therapy of IFX were enrolled in the study. Peripheral blood samples pretreatment were collected. Concentrations of 15 cytokines were measured...

...) drugs in inflammatory bowel disease patients are lacking. Aim: To compare the effectiveness and tolerability of anti-TNF-α drugs used in clinical practice in a cohort of patients with moderate-to-severe ulcerative colitis (UC). Methods: Retrospectively, 122 UC patients treated with infliximab (IFX...

...Belén Beltrán; Marisa Iborra; Esteban Sáez-González; Maria R. Marqués-Miñana; Inés Moret; Elena Cerrillo; Luis Tortosa; Guillermo Bastida; Joaquín Hinojosa; Jose Luis Poveda-Andrés; Pilar Nos Introduction: The association between infliximab (IFX) and fecal calprotectin (FC) levels on one hand...

...Isabelle Pauchard; Stéphane Nancey; Florence Hacard; Nicolas Williet; Xavier Roblin; Driffa Moussata; Frédéric Bérard; Bernard Flourié; Gilles Boschetti Background and Aims: One of the reasons for the failure of infliximab (IFX) is immediate hypersensitivity reactions (IHR). We aimed to report...

...Ken Takeuchi; Takahiro Shimoyama; Takayuki Yamamoto Background: This narrative review was to determine which medication, tacrolimus (TAC) or infliximab (IFX), is safer and more effective in the management of active UC. Our literature search identified 5 studies directly comparing the outcomes...

..., no response to the therapy was observed (8 bloody stools, CRP 40 mg/l). According to emergency symptoms, rescue therapy with infliximab (IFX; 5 mg/kg standard induction protocol) was administered a week later. A partial clinical and laboratory response was achieved after the second dose of IFX (4 stools/day...

...Zsuzsanna Vegh; Zsuzsanna Kurti; Peter L. Lakatos Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts...

... monoclonal antibody, infliximab (IFX), was approved in the EU. Key Messages: There has been considerable skepticism regarding the use of biosimilars. Both clinicians and patients have questioned the safety and efficacy of these new drugs. In particular, the extrapolation of treatment effects between patients...

...Jørgen Jahnsen; Kristin Kaasen Jørgensen Background: The first monoclonal antibody biosimilar to be used in clinical practice is the tumour necrosis factor-alpha inhibitor Remsima® (CT-P13). The drug is approved for all indications as the originator infliximab (Remicade®) although clinical efficacy...

...M. Kolar; D. Duricova; M. Bortlik; V. Hruba; N. Machkova; K. Mitrova; K. Malickova; M. Lukas Jr.; Milan Lukas Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients visiting...

... (but not Health Canada) of CT-P13 (Remsima™/Inflectra™) as infliximab (Remicade®) BSs for IBD by indication extrapolation has led to stormy discussions in the IBD community and beyond regarding the scientific adequacy of this decision. However, as we now have to live with BSs, we hope that the impeding automatic...

... of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Aliment Pharmacol Ther 2012;35:284-291. 23. Vermeire S, Noman M, Van Assche G, et al: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease...

... antibodies (increased clearance), (2) concomitant immunosuppression (decreased clearance), (3) increased serum CRP concentration (increased clearance), (4) decreased serum albumin concentration (increased clearance), (5) decreased body weight (increased clearance), and (6) increased fecal infliximab...

..., instructions or products referred to in the content or advertisements. Adalimumab Anti-TNF therapy Crohn’s disease Infliximab Maintenance therapy Thiopurines The question asked in the title of this chapter was devised by the organisers of the symposium and can be variously interpreted...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Adalimumab Drug levels Inflammatory bowel disease Infliximab Thiopurines...

...-thioguinine nucleotide concentrations are associated with a greater likelihood of clinical response. Azathioprine is modestly effective for Crohn’s disease and ulcerative colitis. Toxicity associated with azathioprine includes infection and lymphoma. Anti-TNF therapy with infliximab, adalimumab...

.... However, the recent completion of two large multi-center, double-blind placebo-controlled trials confirmed a role for infliximab for outpatients with refractory, moderate-severe disease with evidence for clinical remissions, mucosal healing, and a reduction in colectomies. Despite this evidence...

... the patient to risks that may be unnecessary. These patients should be systematically evaluated for bile acid diarrhoea, steatorrhoea, bacterial overgrowth, irritable bowel syndrome and depression. Crohn’s disease Infliximab Irritable bowel syndrome Bile salt diarrhoea Bacterial overgrowth...

... to the efficacy of infliximab but with less adverse effects. Infliximab should be reserved only for patients where other therapies failed. Immunosuppression Crohn’s disease Infliximab Step-up therapy Top-down therapy © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright...

.... Crohn’s disease Infliximab Hepatosplenic T cell lymphoma © 2009 S. Karger AG, Basel 2009 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic...